Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration

Overview

For certain cell & gene therapy trials, the intersection of Institutional Review Boards (IRB) and Institutional Biosafety Committees (IBC) is critical for success. This case study illuminates the triumph of WCG in partnership with a Top 10 CRO to fast-track a large, complex clinical trial start-up. 

Results and Summary: 

The collaborative efforts of WCG’s IRB and IBC teams set the standard for a commitment to accelerated workflows and the surpassing of critical milestones in clinical trial management. Achieving an average IRB review time of two days for the study level, and just one day for each site, showcased an unwavering commitment to efficiency. Notably, the teams secured approval for the first site well ahead of schedule, setting an ambitious tone for subsequent successes. For the IBC teams, the focus shifted towards meeting stringent deadlines, notably the tight timelines associated with the BARDA grant. WCG’s emphasis on agility and effectiveness was showcased by a remarkable achievement of securing approvals for 60 sites before the crucial deadline. This accelerated pace not only met the project’s timelines but positioned WCG’s IRB and IBC teams as reliable partners capable of navigating clinical trial complexities with exceptional proficiency. 

Discover how WCG navigated the intricacies of a high-impact project by downloading this case study.